JP2006524650A - 口腔内崩壊錠 - Google Patents
口腔内崩壊錠 Download PDFInfo
- Publication number
- JP2006524650A JP2006524650A JP2006505183A JP2006505183A JP2006524650A JP 2006524650 A JP2006524650 A JP 2006524650A JP 2006505183 A JP2006505183 A JP 2006505183A JP 2006505183 A JP2006505183 A JP 2006505183A JP 2006524650 A JP2006524650 A JP 2006524650A
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- tablet according
- active substance
- microcrystalline cellulose
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006191 orally-disintegrating tablet Substances 0.000 title abstract description 46
- 239000013543 active substance Substances 0.000 claims abstract description 45
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000002245 particle Substances 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 210000000214 mouth Anatomy 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 239000007884 disintegrant Substances 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- -1 exercise promoter Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 9
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 9
- 229960001534 risperidone Drugs 0.000 claims description 9
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 229960000528 amlodipine Drugs 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 229960001475 zolpidem Drugs 0.000 claims description 7
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims description 7
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 6
- 229960000681 leflunomide Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229960005343 ondansetron Drugs 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 6
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 229960005017 olanzapine Drugs 0.000 claims description 5
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 5
- 229960002855 simvastatin Drugs 0.000 claims description 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 5
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 229960005489 paracetamol Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229960000820 zopiclone Drugs 0.000 claims description 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 3
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
- 230000001088 anti-asthma Effects 0.000 claims description 3
- 239000000924 antiasthmatic agent Substances 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 239000002702 enteric coating Substances 0.000 claims description 3
- 238000009505 enteric coating Methods 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 229960005127 montelukast Drugs 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 229960002296 paroxetine Drugs 0.000 claims description 3
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 3
- 229960003089 pramipexole Drugs 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 229940032147 starch Drugs 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 108010061435 Enalapril Proteins 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 230000000648 anti-parkinson Effects 0.000 claims description 2
- 230000000561 anti-psychotic effect Effects 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000000939 antiparkinson agent Substances 0.000 claims description 2
- 239000003435 antirheumatic agent Substances 0.000 claims description 2
- 229960002274 atenolol Drugs 0.000 claims description 2
- 229960005370 atorvastatin Drugs 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000623 carbamazepine Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims description 2
- 229940125692 cardiovascular agent Drugs 0.000 claims description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 2
- 229960000590 celecoxib Drugs 0.000 claims description 2
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 2
- 229960005132 cisapride Drugs 0.000 claims description 2
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001653 citalopram Drugs 0.000 claims description 2
- 229960004170 clozapine Drugs 0.000 claims description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 2
- 229960004166 diltiazem Drugs 0.000 claims description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 2
- 229960001253 domperidone Drugs 0.000 claims description 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001389 doxazosin Drugs 0.000 claims description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 2
- 229960000873 enalapril Drugs 0.000 claims description 2
- 229960002464 fluoxetine Drugs 0.000 claims description 2
- 229960004038 fluvoxamine Drugs 0.000 claims description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 2
- 229960003727 granisetron Drugs 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 2
- 229960001848 lamotrigine Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004503 metoclopramide Drugs 0.000 claims description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001597 nifedipine Drugs 0.000 claims description 2
- 229960000381 omeprazole Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 229960002965 pravastatin Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 229960000620 ranitidine Drugs 0.000 claims description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 2
- 229960003946 selegiline Drugs 0.000 claims description 2
- 229960002073 sertraline Drugs 0.000 claims description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 claims description 2
- 229960001693 terazosin Drugs 0.000 claims description 2
- 229960000351 terfenadine Drugs 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 229960004764 zafirlukast Drugs 0.000 claims description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims 1
- 229960002781 bisoprolol Drugs 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 229960003627 gemfibrozil Drugs 0.000 claims 1
- 239000003326 hypnotic agent Substances 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000003232 water-soluble binding agent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 abstract description 134
- 239000000203 mixture Substances 0.000 description 37
- 108010011485 Aspartame Proteins 0.000 description 14
- 239000000605 aspartame Substances 0.000 description 14
- 229960003438 aspartame Drugs 0.000 description 14
- 235000010357 aspartame Nutrition 0.000 description 14
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 14
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 14
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 14
- 239000011159 matrix material Substances 0.000 description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
- 235000010980 cellulose Nutrition 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 10
- 239000001913 cellulose Substances 0.000 description 10
- 239000008108 microcrystalline cellulose Substances 0.000 description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 10
- 235000019640 taste Nutrition 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 239000008368 mint flavor Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- 230000006835 compression Effects 0.000 description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 238000007907 direct compression Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 235000006679 Mentha X verticillata Nutrition 0.000 description 5
- 235000002899 Mentha suaveolens Nutrition 0.000 description 5
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007916 tablet composition Substances 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- SHIJTGJXUHTGGZ-RVXRQPKJSA-N (3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidin-1-ium;methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 SHIJTGJXUHTGGZ-RVXRQPKJSA-N 0.000 description 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 3
- 208000019505 Deglutition disease Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 235000013980 iron oxide Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960002567 paroxetine mesylate Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229960004343 alendronic acid Drugs 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000011872 intimate mixture Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 2
- 229960001951 montelukast sodium Drugs 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 238000012503 pharmacopoeial method Methods 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000070918 Cima Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960004005 amlodipine besylate Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000012536 packaging technology Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002652 pramipexole dihydrochloride Drugs 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 229960003198 tamsulosin hydrochloride Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VQMNWIMYFHHFMC-UHFFFAOYSA-N tert-butyl 4-hydroxyindole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1O VQMNWIMYFHHFMC-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46302703P | 2003-04-16 | 2003-04-16 | |
| PCT/EP2004/004119 WO2004091585A1 (en) | 2003-04-16 | 2004-04-16 | Orally disintegrating tablets |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524650A true JP2006524650A (ja) | 2006-11-02 |
| JP2006524650A5 JP2006524650A5 (https=) | 2007-06-14 |
Family
ID=33300032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505183A Withdrawn JP2006524650A (ja) | 2003-04-16 | 2004-04-16 | 口腔内崩壊錠 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040265375A1 (https=) |
| EP (1) | EP1613289A1 (https=) |
| JP (1) | JP2006524650A (https=) |
| CN (1) | CN1787811A (https=) |
| AU (1) | AU2004229177A1 (https=) |
| CA (1) | CA2522100A1 (https=) |
| NO (1) | NO20055393L (https=) |
| NZ (1) | NZ542925A (https=) |
| WO (1) | WO2004091585A1 (https=) |
| ZA (1) | ZA200508361B (https=) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007015966A (ja) * | 2005-07-06 | 2007-01-25 | Fujimoto Corporation:Kk | 口腔内崩壊錠 |
| WO2008081774A1 (ja) * | 2006-12-26 | 2008-07-10 | Shionogi & Co., Ltd. | リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤 |
| JP2009196940A (ja) * | 2008-02-22 | 2009-09-03 | Takada Seiyaku Kk | 口腔内速崩壊錠及びその製造法 |
| JP2011506279A (ja) * | 2007-12-08 | 2011-03-03 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 経口で分散可能な錠剤 |
| JP2011213695A (ja) * | 2010-04-02 | 2011-10-27 | Taisho Pharm Ind Ltd | ドネペジル塩酸塩含有口腔内速崩壊錠 |
| JP2012528854A (ja) * | 2009-06-25 | 2012-11-15 | チャバイオ アンド ディオステク株式会社 | 不快味を効果的に隠蔽した経口用速溶フィルム |
| JP2014058461A (ja) * | 2012-09-14 | 2014-04-03 | Sawai Pharmaceutical Co Ltd | オランザピン含有製剤 |
| JP2016079120A (ja) * | 2014-10-15 | 2016-05-16 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 包装により安定性が改善されたオランザピン製剤 |
| WO2016103904A1 (ja) * | 2014-12-25 | 2016-06-30 | 株式会社ダイセル | 超速崩壊錠剤及びその製造方法 |
| JP2016529314A (ja) * | 2013-09-06 | 2016-09-23 | アデア ファーマシューティカルズ，インコーポレイテッド | 好酸球性食道炎のためのコルチコステロイド含有口腔内崩壊錠組成物 |
| JP2021134217A (ja) * | 2020-02-26 | 2021-09-13 | 日新製薬株式会社 | 被覆層を有する口腔内崩壊錠 |
| US11896710B2 (en) | 2016-08-18 | 2024-02-13 | Ellodi Pharmaceuticals, L.P. | Methods of treating eosinophilic esophagitis |
| US12290598B2 (en) | 2009-10-01 | 2025-05-06 | Ellodi Pharmaceuticals, L.P. | Orally administered corticosteroid compositions |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| DE60120104T2 (de) | 2001-03-20 | 2006-09-21 | Schwarz Pharma Ag | Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz |
| DK1243263T3 (da) | 2001-03-21 | 2003-03-17 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte |
| US20040161459A1 (en) * | 2002-12-31 | 2004-08-19 | Ngoc Do | Fast-dissolve tablet technology |
| WO2005034921A1 (en) * | 2003-10-07 | 2005-04-21 | Andrx Pharmaceuticals Llc | Rapidly disintegrating formulation |
| ATE522507T1 (de) * | 2003-10-10 | 2011-09-15 | Synhton B V | Montelukast in fester phase |
| CZ300438B6 (cs) * | 2003-11-25 | 2009-05-20 | Pliva Hrvatska D.O.O. | Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu |
| US20050272720A1 (en) * | 2004-01-27 | 2005-12-08 | Rolf Keltjens | Process for making olanzapine Form I |
| ATE504588T1 (de) * | 2004-01-27 | 2011-04-15 | Synthon Bv | Stabile salze von olanzapin |
| JP5179757B2 (ja) | 2004-02-17 | 2013-04-10 | トランセプト ファーマシューティカルズ， インコーポレイティド | 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法 |
| US7501517B2 (en) * | 2004-04-30 | 2009-03-10 | Synthon Ip, Inc. | Process for making montelukast and intermediates therefor |
| US7829716B2 (en) * | 2004-04-30 | 2010-11-09 | Synthon Pharmaceuticals, Inc. | Process for making montelukast and intermediates therefor |
| DE102004028940A1 (de) * | 2004-06-15 | 2006-01-12 | Krka Tovarna Zdravil, D.D. | Oral zerfallende pharmazeutische Zusammensetzung, die Risperidon enthält |
| EA014055B1 (ru) | 2004-08-27 | 2010-08-30 | Шварц Фарма Аг | Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами |
| US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
| ATE415148T1 (de) | 2004-10-19 | 2008-12-15 | Krka Tovarna Zdravil D D Novo | Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid |
| GB0423800D0 (en) | 2004-10-27 | 2004-12-01 | Orexo Ab | New pharmaceutical formulations |
| JP2008523044A (ja) * | 2004-12-13 | 2008-07-03 | マクニール−ピーピーシー・インコーポレーテツド | 医薬品有効成分を安定化する組成物および方法 |
| JP2008525313A (ja) | 2004-12-27 | 2008-07-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗痴呆薬の安定化方法 |
| CZ297214B6 (cs) * | 2005-02-02 | 2006-10-11 | Zentiva, A. S. | Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby |
| IS7724A (is) * | 2005-03-02 | 2006-09-03 | Actavis Group | Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat |
| PL385455A1 (pl) * | 2005-04-22 | 2008-11-24 | Teva Pharmaceuticals Usa,Inc. | Doustna rozpadająca się farmaceutyczna tabletka preparatów olanzapiny |
| ZA200710205B (en) * | 2005-05-25 | 2009-03-25 | Transcept Pharmaceuticals Inc | Solid compositions and methods for treating middle-of-the night insomnia |
| US20070287740A1 (en) | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
| EP1883408A4 (en) * | 2005-05-25 | 2009-11-11 | Transcept Pharmaceuticals Inc | SOLID COMPOSITIONS AND METHODS FOR TREATMENT OF INSOMNIA IN THE NIGHT |
| WO2007002518A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Delayed release or extended-delayed release dosage forms of pramipexole |
| DE102005033943A1 (de) * | 2005-07-20 | 2007-02-22 | Hexal Ag | Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für ein Neuroleptikum |
| JP5241681B2 (ja) * | 2005-08-01 | 2013-07-17 | 大日本住友製薬株式会社 | アムロジピン含有粒子およびそれからなる口腔内崩壊錠 |
| JP4439499B2 (ja) * | 2005-08-01 | 2010-03-24 | 大日本住友製薬株式会社 | アムロジピン含有粒子およびそれからなる口腔内崩壊錠 |
| WO2007018192A1 (ja) * | 2005-08-10 | 2007-02-15 | Shionogi & Co., Ltd. | 口腔内崩壊錠剤 |
| WO2007020079A2 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | Orally disintegratable simvastatin tablets |
| WO2007020080A1 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | A process for making olanzapine form i |
| GB0518129D0 (en) * | 2005-09-06 | 2005-10-12 | Arrow Int Ltd | Ramipril formulation |
| FR2891147B1 (fr) * | 2005-09-28 | 2007-12-07 | Ethypharm Sa | Comprimes orodispersibles de principes actifs amers |
| US20070093471A1 (en) * | 2005-10-26 | 2007-04-26 | Alamo Pharmaceuticals, Llc | Compositions and methods for the administration clozapine formulations which modulate body weight |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| AR057908A1 (es) * | 2005-11-18 | 2007-12-26 | Synthon Bv | Proceso para preparar montelukast e intermediarios del mismo |
| AU2006322314A1 (en) * | 2005-11-18 | 2007-06-14 | Synthon B.V. | Zolpidem tablets |
| DE102005060377A1 (de) * | 2005-12-16 | 2007-06-21 | Ratiopharm Gmbh | Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung |
| JP2009519334A (ja) * | 2005-12-20 | 2009-05-14 | テバ ファーマシューティカル インダストリーズ リミティド | ランソプラゾール経口崩壊錠剤 |
| CA2632039A1 (en) * | 2005-12-23 | 2007-06-28 | Lek Pharmaceuticals D.D. | Bursting pellets |
| EA021960B1 (ru) † | 2005-12-30 | 2015-10-30 | Крка, Товарна Здравил, Д.Д., Ново Место | Таблетка, содержащая фармацевтически приемлемую соль монтелукаста в аморфной форме, и способ ее получения |
| CN103211779B (zh) * | 2006-01-27 | 2016-03-16 | 阿代尔制药股份有限公司 | 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统 |
| RU2428176C2 (ru) * | 2006-01-27 | 2011-09-10 | Юранд, Инк. | Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты |
| EP1815857A1 (en) * | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| WO2007107297A1 (en) * | 2006-03-17 | 2007-09-27 | Synthon B.V. | Montelukast amantadine salt |
| WO2007111375A1 (ja) * | 2006-03-24 | 2007-10-04 | Kowa Company, Ltd. | 口腔内速崩壊性錠剤 |
| WO2007134845A2 (en) * | 2006-05-18 | 2007-11-29 | Synthon B.V. | Olanzapine pharmaceutical composition |
| US20070281014A1 (en) * | 2006-06-01 | 2007-12-06 | Cima Labs, Inc. | Prednisolone salt formulations |
| US8637076B2 (en) * | 2006-06-01 | 2014-01-28 | Cima Labs Inc. | Prednisolone salt formulations |
| EA019757B1 (ru) | 2006-06-15 | 2014-06-30 | ЮСиБи ФАРМА ГМБХ | Фармацевтическая композиция с синергетическим противосудорожным эффектом |
| US20080008743A1 (en) * | 2006-07-06 | 2008-01-10 | Forest Laboratories Holdings Limited | Orally Dissolving Formulations of Memantine |
| JP2008044870A (ja) * | 2006-08-11 | 2008-02-28 | Elmed Eisai Kk | 医薬組成物及びその製造方法 |
| CL2007002807A1 (es) * | 2006-09-29 | 2008-04-11 | Synthon Bv | Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren |
| WO2008058355A2 (en) * | 2006-11-16 | 2008-05-22 | Walter Santos Junior | Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases |
| BRMU8602968U (pt) * | 2006-11-16 | 2008-09-30 | Jr Walter Santos | medicamento "ramipril + metformina" em forma combinada para doenças cardiovasculares |
| GB2444904B (en) * | 2006-12-05 | 2008-11-05 | Michael Hilary Burke | A Process For The Preparation of an Orally Administrable Unit Dose Tablet |
| CN101269014B (zh) * | 2007-03-21 | 2012-11-14 | 江苏万特制药有限公司 | 一种利培酮的口腔崩解片及其制备方法 |
| CA2721133C (en) * | 2007-04-13 | 2018-11-06 | Somaxon Pharmaceuticals, Inc. | Low-dose doxepin formulations and methods of making and using the same |
| EP1997480A1 (en) * | 2007-06-01 | 2008-12-03 | The Jordanian Pharmaceutical Manufacturing Co. | Mineral-fiber solid dispersion, method for preparing the same and use thereof as pharmaceutical tableting aid |
| TWI547282B (zh) | 2007-07-02 | 2016-09-01 | 愛戴爾製藥股份有限公司 | 樂命達之口服分解錠劑組合物 |
| EP2044929A1 (en) * | 2007-10-04 | 2009-04-08 | Laboratorios del Dr. Esteve S.A. | Oral fast distintegrating tablets |
| ES2455195T3 (es) * | 2007-11-21 | 2014-04-14 | Dainippon Sumitomo Pharma Co., Ltd. | Comprimido que se disgrega en la cavidad oral |
| CN102046602A (zh) * | 2008-04-25 | 2011-05-04 | 斯索恩有限公司 | 制备孟鲁司特中间体的方法 |
| US20100016265A1 (en) * | 2008-07-16 | 2010-01-21 | Qaiser Yusuf | Anti-inflammatory composition and method for preparation |
| CN101766605B (zh) * | 2008-12-29 | 2014-02-19 | 北京德众万全药物技术开发有限公司 | 包含普拉克索的可在口中分散的药物组合物 |
| JP2012521393A (ja) | 2009-03-26 | 2012-09-13 | ロイヤル カレッジ オブ サージェオンズ イン アイルランド | 口腔内分散性錠剤 |
| TR200903293A1 (tr) * | 2009-04-28 | 2010-11-22 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Oral yolla dağılan olanzapin tablet. |
| US20110097401A1 (en) | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| CA2773003A1 (en) * | 2009-09-15 | 2011-03-24 | Ratiopharm Gmbh | Orally disintegrating pharmaceutical dosage form containing aripiprazole |
| TR200907554A1 (tr) * | 2009-10-06 | 2011-04-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Oral yolla dağılan pramıpexole bileşimleri. |
| CN102058549B (zh) * | 2009-11-17 | 2014-08-27 | 北京万全阳光医学技术有限公司 | 一种含非那雄胺的口腔崩解片及其制备方法 |
| CN101716151B (zh) * | 2009-12-24 | 2012-06-27 | 杭州康恩贝制药有限公司 | 一种快速溶出的非那雄胺口服片剂及制备方法 |
| EP2524689B1 (en) * | 2009-12-28 | 2016-10-05 | Nipro Corporation | Method for producing donepezil tablets |
| US8703203B2 (en) * | 2010-07-08 | 2014-04-22 | Ratiopharm Gmbh | Oral dosage form of deferasirox |
| CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| EP2468254A1 (en) * | 2010-12-15 | 2012-06-27 | Hexal AG | Orally disintegrating tablet having a taste masking effect |
| CN102727452B (zh) * | 2011-04-01 | 2014-12-24 | 成都康弘药业集团股份有限公司 | 一种含右佐匹克隆的颗粒及其制备方法 |
| WO2013095314A1 (en) * | 2011-12-19 | 2013-06-27 | Mahmut Bilgic | Pharmaceutical formulations comprising risperidone |
| WO2014090386A1 (en) * | 2012-12-11 | 2014-06-19 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Orally disintegrating tablet containing asenapine |
| EP2964243B1 (en) | 2013-03-06 | 2022-11-23 | Capsugel Belgium NV | Curcumin solid lipid particles and methods for their preparation and use |
| US20150025112A1 (en) * | 2013-07-19 | 2015-01-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally disintegrating tablet formulations of donepezil |
| EP3071199A2 (en) * | 2013-11-22 | 2016-09-28 | Genzyme Corporation | Novel methods for treating neurodegenerative diseases |
| CN104784047B (zh) * | 2014-01-16 | 2018-09-21 | 南京瑞尔医药有限公司 | 一种非那雄胺组合物 |
| CN105012253A (zh) * | 2014-04-24 | 2015-11-04 | 南京长澳医药科技有限公司 | 一种盐酸普拉克索口腔崩解片及其制备方法 |
| EP3766480A1 (en) * | 2014-06-10 | 2021-01-20 | Capsugel Belgium NV | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use |
| CN104027319A (zh) * | 2014-06-25 | 2014-09-10 | 万特制药(海南)有限公司 | 一种塞来昔布分散片及其制备方法 |
| CA3018828C (en) | 2014-09-17 | 2021-05-11 | Steerlife India Private Limited | Effervescent composition and method of making it |
| CN104382895A (zh) * | 2014-10-22 | 2015-03-04 | 湖南明瑞制药有限公司 | 一种辛伐他汀组合物 |
| CN104523645A (zh) * | 2014-11-20 | 2015-04-22 | 美吉斯制药（厦门）有限公司 | 甲磺酸帕罗西汀片芯及其包衣片的制备方法 |
| US11324699B2 (en) | 2014-12-04 | 2022-05-10 | Capsugel Belgium Nv | Lipid multiparticulate formulations |
| CN104771761A (zh) * | 2015-03-19 | 2015-07-15 | 深圳国源国药有限公司 | 一种创新药用辅料硅化微晶纤维素及其制备方法 |
| CN105147627B (zh) * | 2015-08-19 | 2019-04-12 | 天津红日药业股份有限公司 | 一种含有盐酸普拉克索的药物组合物及其制备方法 |
| WO2017098481A1 (en) | 2015-12-12 | 2017-06-15 | Steerlife India Private Limited | Effervescent compositions of metformin and processes for preparation thereof |
| RU2619213C1 (ru) * | 2016-01-25 | 2017-05-12 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма зафирлукаста немедленного высвобождения и способ ее получения |
| US11110035B1 (en) | 2016-02-05 | 2021-09-07 | Gram Tactical Llc | Tactical medicine dispensers |
| CN108938580B (zh) * | 2017-05-26 | 2022-09-27 | 万全万特制药江苏有限公司 | 盐酸帕罗西汀口崩片 |
| CN109864975B (zh) * | 2017-12-04 | 2021-10-08 | 成都康弘药业集团股份有限公司 | 一种阿立哌唑的口腔崩解片及其制备方法 |
| WO2019175100A1 (en) * | 2018-03-11 | 2019-09-19 | Nanologica Ab | Porous silica particles for use in compressed pharmaceutical dosage form |
| CN110840850B (zh) * | 2018-07-24 | 2023-03-17 | 烟台药物研究所 | 一种高生物利用度的塞来昔布冻干口崩片及其制备方法 |
| AU2019334202A1 (en) | 2018-09-06 | 2021-03-25 | Innopharmascreen, Inc. | Methods and compositions for treatment of asthma or parkinson's disease |
| CN116801888A (zh) * | 2020-12-31 | 2023-09-22 | 株式会社泰俊制药 | 用于结肠清洁的口服固体制剂 |
| GB2636158A (en) * | 2023-12-01 | 2025-06-11 | Novumgen Ltd | An orally disintegrating tablet containing amlodipine or pharmaceutically acceptable salts thereof and the process of preparing the same |
| GB2636182A (en) * | 2023-12-04 | 2025-06-11 | Novumgen Ltd | An orally disintegrating tablet of paroxetine and its process of preparation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US50312A (en) * | 1865-10-03 | Improvement in handle attachments to small-arms | ||
| US4517179A (en) * | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
| US5464632C1 (en) * | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
| US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
| US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| US6471994B1 (en) * | 1995-01-09 | 2002-10-29 | Edward Mendell Co., Inc. | Pharmaceutical excipient having improved compressibility |
| DE19530575A1 (de) * | 1995-08-19 | 1997-02-20 | Gruenenthal Gmbh | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz |
| FR2766089B1 (fr) * | 1997-07-21 | 2000-06-02 | Prographarm Lab | Comprime multiparticulaire perfectionne a delitement rapide |
| US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| DK2263660T3 (en) * | 1998-05-18 | 2018-01-02 | Takeda Pharmaceuticals Co | Orally disintegrating tablets. |
| US6190696B1 (en) * | 1998-06-08 | 2001-02-20 | Pieter J. Groenewoud | Stabilized thyroxine medications |
| US7815937B2 (en) * | 1998-10-27 | 2010-10-19 | Biovail Laboratories International Srl | Quick dissolve compositions and tablets based thereon |
| KR20020062323A (ko) * | 1999-12-06 | 2002-07-25 | 펜웨스트 파머슈티칼즈 컴파니 | 제약학적 초붕해제 |
| US6399101B1 (en) * | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
| BR0206164A (pt) * | 2001-07-31 | 2003-10-28 | Lundbeck & Co As H | Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida |
| MXPA04007428A (es) * | 2002-02-01 | 2004-10-11 | Pfizer Prod Inc | Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido. |
| SI21221A (sl) * | 2002-06-21 | 2003-12-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Hitro razpadljive tablete |
-
2004
- 2004-04-15 US US10/824,619 patent/US20040265375A1/en not_active Abandoned
- 2004-04-16 AU AU2004229177A patent/AU2004229177A1/en not_active Abandoned
- 2004-04-16 JP JP2006505183A patent/JP2006524650A/ja not_active Withdrawn
- 2004-04-16 NZ NZ542925A patent/NZ542925A/en unknown
- 2004-04-16 EP EP04727894A patent/EP1613289A1/en not_active Withdrawn
- 2004-04-16 CN CN200480013099.3A patent/CN1787811A/zh active Pending
- 2004-04-16 CA CA002522100A patent/CA2522100A1/en not_active Abandoned
- 2004-04-16 WO PCT/EP2004/004119 patent/WO2004091585A1/en not_active Ceased
-
2005
- 2005-10-14 ZA ZA200508361A patent/ZA200508361B/en unknown
- 2005-11-15 NO NO20055393A patent/NO20055393L/no not_active Application Discontinuation
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007015966A (ja) * | 2005-07-06 | 2007-01-25 | Fujimoto Corporation:Kk | 口腔内崩壊錠 |
| WO2008081774A1 (ja) * | 2006-12-26 | 2008-07-10 | Shionogi & Co., Ltd. | リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤 |
| JP2013040199A (ja) * | 2006-12-26 | 2013-02-28 | Shionogi & Co Ltd | リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤 |
| JP5275815B2 (ja) * | 2006-12-26 | 2013-08-28 | 塩野義製薬株式会社 | リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤 |
| JP2011506279A (ja) * | 2007-12-08 | 2011-03-03 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 経口で分散可能な錠剤 |
| JP2015038123A (ja) * | 2007-12-08 | 2015-02-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 経口で分散可能な錠剤 |
| JP2009196940A (ja) * | 2008-02-22 | 2009-09-03 | Takada Seiyaku Kk | 口腔内速崩壊錠及びその製造法 |
| JP2012528854A (ja) * | 2009-06-25 | 2012-11-15 | チャバイオ アンド ディオステク株式会社 | 不快味を効果的に隠蔽した経口用速溶フィルム |
| US12290598B2 (en) | 2009-10-01 | 2025-05-06 | Ellodi Pharmaceuticals, L.P. | Orally administered corticosteroid compositions |
| JP2011213695A (ja) * | 2010-04-02 | 2011-10-27 | Taisho Pharm Ind Ltd | ドネペジル塩酸塩含有口腔内速崩壊錠 |
| JP2014058461A (ja) * | 2012-09-14 | 2014-04-03 | Sawai Pharmaceutical Co Ltd | オランザピン含有製剤 |
| JP2016529314A (ja) * | 2013-09-06 | 2016-09-23 | アデア ファーマシューティカルズ，インコーポレイテッド | 好酸球性食道炎のためのコルチコステロイド含有口腔内崩壊錠組成物 |
| US12447157B2 (en) | 2013-09-06 | 2025-10-21 | Ellodi Pharmaceuticals, L.P. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| US12310976B2 (en) | 2013-09-06 | 2025-05-27 | Ellodi Pharmaceuticals, L.P. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| JP2016079120A (ja) * | 2014-10-15 | 2016-05-16 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 包装により安定性が改善されたオランザピン製剤 |
| WO2016103904A1 (ja) * | 2014-12-25 | 2016-06-30 | 株式会社ダイセル | 超速崩壊錠剤及びその製造方法 |
| KR20170100544A (ko) * | 2014-12-25 | 2017-09-04 | 주식회사 다이셀 | 초고속 붕해 정제 및 그 제조 방법 |
| JPWO2016103904A1 (ja) * | 2014-12-25 | 2017-10-05 | 株式会社ダイセル | 超速崩壊錠剤及びその製造方法 |
| JP2019131597A (ja) * | 2014-12-25 | 2019-08-08 | 株式会社ダイセル | 超速崩壊錠剤及びその製造方法 |
| KR102431738B1 (ko) * | 2014-12-25 | 2022-08-10 | 주식회사 다이셀 | 초고속 붕해 정제 및 그 제조 방법 |
| EP3238712B1 (en) * | 2014-12-25 | 2023-11-01 | Daicel Corporation | Very rapidly disintegrating tablet, and method for producing same |
| US12059494B2 (en) | 2016-08-18 | 2024-08-13 | Ellodi Pharmaceuticals, L.P. | Methods of treating eosinophilic esophagitis |
| US11896710B2 (en) | 2016-08-18 | 2024-02-13 | Ellodi Pharmaceuticals, L.P. | Methods of treating eosinophilic esophagitis |
| JP7219979B2 (ja) | 2020-02-26 | 2023-02-09 | 日新製薬株式会社 | 被覆層を有する口腔内崩壊錠 |
| JP2021134217A (ja) * | 2020-02-26 | 2021-09-13 | 日新製薬株式会社 | 被覆層を有する口腔内崩壊錠 |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ542925A (en) | 2007-04-27 |
| WO2004091585A1 (en) | 2004-10-28 |
| US20040265375A1 (en) | 2004-12-30 |
| CN1787811A (zh) | 2006-06-14 |
| NO20055393D0 (no) | 2005-11-15 |
| NO20055393L (no) | 2006-01-16 |
| EP1613289A1 (en) | 2006-01-11 |
| CA2522100A1 (en) | 2004-10-28 |
| AU2004229177A1 (en) | 2004-10-28 |
| ZA200508361B (en) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006524650A (ja) | 口腔内崩壊錠 | |
| ES2347968T3 (es) | Preparacion solida que se disgrega rapidamente. | |
| JP4920798B2 (ja) | ２種以上の粒子を含有する口腔内速崩壊錠 | |
| AU2005307052B2 (en) | Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane | |
| ES2668381T3 (es) | Comprimidos de desintegración por vía oral y métodos de fabricación | |
| CN101141951B (zh) | 舌下包衣片 | |
| JP2018058911A (ja) | 口腔内崩壊錠 | |
| US20100080847A1 (en) | Medicinal compositions quickly disintegrating in the oral cavity and process for producing the same | |
| CN1747723B (zh) | 含活性成分混合物的组合物及其制备方法 | |
| JP2007509155A (ja) | クエチアピンを含有する薬剤 | |
| WO2013161823A1 (ja) | 口腔内崩壊錠及びその製造方法 | |
| JP7336388B2 (ja) | 錠剤及びその製造方法 | |
| CA2440361A1 (en) | Intraorally rapidly disintegrable preparation | |
| CN101888834A (zh) | 口服分散片 | |
| MX2009002371A (es) | Tecnologia para administracion flotante programable. | |
| JPH0251402B2 (https=) | ||
| JP2012036140A (ja) | 苦味を抑制した速崩壊錠 | |
| JP2007532620A (ja) | 両親媒性デンプンを含む医薬組成物 | |
| WO2007074856A1 (ja) | 口腔内崩壊性固形製剤の製造法 | |
| JPWO2005055989A1 (ja) | 薬物含有粒子および該粒子を含む固形製剤 | |
| KR20110133060A (ko) | 구강내 속붕성 정제 | |
| JP5572321B2 (ja) | 被覆微粒子含有口腔内崩壊錠 | |
| JP2020169143A (ja) | アジルサルタンを含有する錠剤 | |
| JP2005029557A (ja) | 口腔内速崩壊性錠剤およびその製造方法 | |
| KR100457458B1 (ko) | 속용정 및 그의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070409 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070409 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20080710 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080710 |